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Background: Diabetes mellitus and thyroid diseases frequently coexist. In order to evaluate how thyroid disorders
interfere with glycemic control, we analysed insulin-treated type 2 diabetes patients with thyroid disease.
Methods: Diabetes patients (n = 1.957) were retrospectively investigated. We focused on type 2 diabetes patients
who had been admitted for insulin-treatment and diagnosed thyroid diseases (n = 328). Patients were divided into
three groups according to thyroid disease manifestation in relation to diabetes onset: prior to (group 1), same year
(group 2) and thyroid disease following diabetes (group 3).
Results: Out of all diabetes patients 27.3% had a thyroid disorder with more women (62.2%) being affected
(p < 0.001). Thyroid disease was predominantly diagnosed after diabetes onset. Patients with type 2 diabetes and
prior appearance of thyroid disease required insulin therapy significantly earlier (median insulin-free period: 2.5 yrs;
Q1 = 0.0, Q3 = 8.25) compared to patients who had thyroid dysfunction after diabetes onset (median insulin-free
period: 8.0 yrs; Q1 = 3.0, Q3 = 12.0; p < 0.001). Age at diabetes onset correlated with insulin-free period (p < 0.001).
Conclusions: Thyroid disease may be a marker of a distinct metabolic trait in type 2 diabetes potentially requiring
earlier insulin treatment.
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Thyroid diseases have been described to be more common
in diabetes than expected. In the general population their
prevalence range between 6.6% in the UK [1] and 5.9% in
the US National Health and Nutrition Examination Survey
(NHANES III) [2]. In contrast, diabetes mellitus shows a
higher prevalence - 10.8% in the community and up to
13.4% in a hospital diabetic clinic [3,4].
These endocrinopathies influence each other in multiple
ways. Poorly controlled diabetes mellitus may affect thy-
roid metabolism as uncontrolled hyperglycemia alters
plasma triiodothyronine (T3) and in part thyroxine (T4)
levels [5]. Hyperinsulinaemia can also be associated with
goitre as well as with thyroid nodules [6,7]. Conversely,
hyperthyroidism can aggravate glycemia by a stimulation
of glucose absorption, glycogenolysis and hepatic glucose
production [8] as well as enhanced insulin resistance [9]
and shortened half-life of circulating insulin concentrations* Correspondence: badenhoop@em.uni-frankfurt.de
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unless otherwise stated.[10]. Reverse effects have been observed in patients with
hypothyroid metabolism [11].
These interactions need to be understood for clinical
management. The present study analysed the impact of
thyroid diseases on glycemic control comparing insulin-
treated type 2 diabetes patients with thyroid disorder
manifestation prior to, concomitant with and following
diabetes onset.Subjects and methods
Subjects
We retrospectively evaluated 1.957 diabetes patients (843
females, 1.114 males) who were admitted to the Department
of Endocrinology & Diabetes at the University Hospital
Frankfurt am Main, Germany, between January 1, 2002,
and December 31, 2010. The retrospective study on anon-
ymized patient data was performed in compliance with
the Helsinki declaration.
Patients were classified as having coexistent thyroid dys-
functions based on information on autoantibodies against
thyroid peroxidase (anti-TPO), thyroglobulin (anti-Tg) andLtd. This is an Open Access article distributed under the terms of the Creative
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triiodothyronine (fT3), free thyroxine (fT4), thyroid-
stimulating hormone (TSH)), thyroid volume (sonog-
raphy) as well as thyroid disease treatment for individual
diagnoses according to the following criteria:
Hypothyroidism – including subclinical – defined as
serum TSH levels greater than the corresponding refer-
ence range associated with normal or decreased serum
fT4 and fT3 values. Hyperthyroidism – including sub-
clinical – diagnosed by suppressed serum TSH levels
with normal or increased concentrations of fT4 and fT3.
Goitre defined as thyroid enlargement with a total glan-
dular volume exceeding 18 ml in women and 25 ml in
men, corresponding to mean thyroid volume +3 SD in
iodine-sufficient populations [12]. This definition has
also been applied in other European studies on the epi-
demiology of thyroid disorders [13]. Since our patients
grew up during iodine deficient periods, we decided to
apply this definition bearing in mind that the standards
to define normal thyroid volumes are changing [14,15].
Hashimoto’s thyroiditis confirmed by the presence of el-
evated anti-TPO or anti-Tg antibodies associated with
primary hypothyroidism and, if available, by cytological
evidence of lymphocytic infiltration and an ultrasound
image of hypoechogenicity. Graves’ disease was diag-
nosed by hyperthyroidism with either diffuse goitre,
positive TRAb or the presence of ophthalmopathy, but
not all of our patients were thyroid antibody tested. For
statistical analyses Hashimoto’s thyroiditis and Graves’
disease were subsumed as autoimmune thyroid disease
(AITD).
For closer investigations we focused on insulin-treated
type 2 diabetes patients (diagnosed based on WHO cri-
teria) with coexistent thyroid dysfunctions (n = 328) and
additional available parameters: body height and weight,
date of insulin initiation and titres of autoantibodies
against glutamate decarboxylase (anti-GAD). These pa-
tients were divided into three groups: thyroid disease
manifestation prior to (group 1), same year (group 2)
and following diabetes mellitus onset (group 3). Due to
incomplete parameters in some patients, the total num-
ber of patients varies in some comparisons (cf. Results).
Statistical analysis
The Statistical analysis was carried out by software SPSS
version 11.5 and Bias Statistical package version 10. The
Kolmogorov test was applied to test for normal distribu-
tion of the data. Due to a missing normal distribution,
two groups of quantitative variables were calculated and
compared using Mann-Whitney U test, whereas com-
parison of more than two groups was performed by the
Kruskal-Wallis test. Data on quantitative parameters
were expressed as median and quartilesQ1 (first quartile)
and Q3 (third quartile). Data on qualitative parameterswere expressed as percentages as well as absolute values,
and were compared by the chi-square (χ2) test or the
Fisher’s exact test. Statistical dependence was measured
by Spearman's rank correlation coefficient (rs), its degree
of influence was interpreted by the coefficient of deter-
mination (rs
2). The level of statistical significance was set
at p < 0.05.
Results
Study population
Between January 1, 2002, and December 31, 2010, a total
of 1.957 diabetes patients were admitted as inpatients to
the Department of Endocrinology & Diabetes at the
University Hospital Frankfurt am Main, Germany. In
535 (27.3%) diabetes patients a thyroid disease had been
diagnosed: hypothyroidism (n = 349), hyperthyroidism
(n = 194), Graves’ disease (n = 37), Hashimoto’s thyroid-
itis (n = 145), goitre (n = 221), autonomously function-
ing thyroid (AFT, n = 22), thyroid carcinoma (n = 5). 124
(23.2%) of them did not receive any thyroid treatment
so far. A clear majority (n = 225) developed their thyroid
disease after diabetes onset, whereas due to missing in-
formation 212 patients could not be classified in this re-
gard. With advancing age manifestations of thyroid
disease steadily increased up to a peak in the seventh
decade. In 58.4% of the patients thyroid disease had
been diagnosed after the age of 50.
Diabetes patients with coexisting thyroid disease con-
sisted of 202 men (37.8%) and 333 women (62.2%) whilst
those without thyroid disorders presented a statistically
significantly higher percentage of men (64.1% men (n =
912), 35.9% women (n = 510), p < 0.001). Due to the large
number of patients without thyroid disease, 560 were ran-
domly selected for further analysis resulting in 559 finally
included in the study. A comparison of median HbA1c
values was performed in type 2 diabetes patients. Patients
with thyroid dysfunction had significantly lower median
levels of HbA1c (7.2%; Q1 = 6.5, Q3 = 8.2) compared to
those without thyroid dysfunction (7.5%; Q1 = 6.6, Q3 = 8.9;
p < 0.01) and this difference was not explained by gender.
Insulin-treated type 2 diabetes patients with thyroid
dysfunction
Insulin-treated type 2 diabetes patients with coexistent
thyroid dysfunctions (n = 328) were divided into three
groups according to their sequence of diagnoses when
known (140 patients could not be classified resulting in
188 patients for following analyses): 133 (70.7%) had thy-
roid disease diagnosed after diabetes onset (group 3)
whereas less patients developed thyroid diseases prior to
(group 1; n = 46; 24.5%) or within the same year (group
2; n = 9; 4.8%) of diabetes onset.
Sex ratio and the medians of age, age at diabetes and
thyroid disease onset, BMI (body mass index) and
Figure 1 Correlation between age at diabetes onset and
insulin-free period (n = 283).
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hort (n = 188) are listed in Table 1. Some data was par-
tially missing: body height in 6 patients, date of insulin
initiation in 23 patients.
Statistically significant differences were observed for age
at diabetes onset (p < 0.01): Patients of group 1 (p < 0.01)
and 2 (p < 0.05) were significantly older at diabetes onset
when compared to patients of group 3. Group 2 com-
prised the eldest patients. Contrasting results were found
for age at thyroid disease onset: Patients with thyroid dis-
ease prior to diabetes onset (group 1) were significantly
younger at thyroid disease onset than patients with con-
comitant (group 2; p < 0.01) or subsequent manifestation
of thyroid disease (group 3; p < 0.001). BMI did not differ
statistically significantly among the groups with high me-
dian values between 28.1 kg/m2 and 30.6 kg/m2.
As a measure of individual beta-cell reserve for metabolic
control, the time between diabetes onset and initiation of
insulin substitution, i.e. the insulin-free period, was inves-
tigated in the different groups. With a median value of
8.0 years (Q1 = 3.0, Q3 = 12.0) patients with thyroid disease
diagnosed after diabetes mellitus (group 3) required insulin
therapy significantly later when compared to patients with
thyroid disease diagnosed prior to (group 1; p < 0.001) or
within the same year (group 2; p < 0.001) of diabetes onset.
A comparison of group 1 (2.5 yrs; Q1 = 0.0, Q3 = 8.25) and
2 (0.0 yrs; Q1 = 0.0, Q3 = 0.75) also showed a significant
difference (p < 0.05). Patients of group 3 developed thyroid
diseases on average only after the initiation of insulin
treatment.
An investigation of possible influencing factors showed
no correlation between BMI and insulin-free period
(p > 0.05). However, a clear negative correlation was ob-
served between age at diabetes onset and insulin-free
period (p < 0.001; rs = -0.364, rs
2 = 13.3%, Figure 1). The
older the patient the sooner insulin treatment was started.
Frequencies of positive antibodies (anti-GAD, anti-
TPO, anti-Tg), thyroid diseases, thyroid treatment (in-
cluding partial and complete thyroidectomy, radioiodine
and oral medication) and Levothyroxine supplementa-
tion in particular in groups 1 to 3 and in the total cohortTable 1 Sex ratio and median values of quantitative paramet
insulin-free period)
Group 1 Group 2
Sex - male/female 8/38 5/4
Age [yrs] 61.5 54.0
Age at diabetesonset 53.0 60.0
Age at thyroid disease onset 43.0 60.0
BMI [kg/m2] 28.7 28.1
Insulin-free period [yrs] 2.5 0.0
Group definition: Thyroid disease diagnosed prior to (group 1), within the same yea
BMI: Body Mass Index.(n = 188) are detailed in Table 2. Data was partially miss-
ing: titres of anti-GAD in 144 patients, titres of anti-
TPO in 64 patients, titres of anti-Tg in 65 patients.
Only one patient – belonging to group 3 – was found
to be anti-GAD-positive, whereas no patient of group 1
or 2 was anti-GAD-positive. No significant differences
were observed for positivity of thyroid autoantibodies
(anti-TPO, anti-Tg). However, patients in group 2 had
the highest frequency of positive results for anti-TPO as
well as anti-Tg.
We then focused on primary thyroid dysfunction. Statis-
tically significant differences were found in the prevalence
of hyperthyroidism among individual groups (p < 0.05).
The prevalence of hyperthyroidism was highest in group 3
(41.4%) being significantly more frequent than in group 1
(17.4%; p < 0.01). With advancing age the prevalence of
hyperthyroidism increased more compared to the preva-
lence of other thyroid disorders. Whereas hypothyroidism
was diagnosed in 40.8% after the age of 59, this applied to
59.0% of the patients with hyperthyroidism. After exclud-
ing all patients with hyperthyroidism from the analysis,ers (age, age at diabetes and thyroid disease onset, BMI,
Group 3 Total Statistical significance
61/72 74/114 p < 0.01
60.0 61.0 ns
49.0 50.5 p < 0.01
62.0 60.0 p < 0.001
30.6 30.3 ns
8.0 7.0 p < 0.001
r (group 2) or after (group 3) diabetes onset.
Table 2 Frequencies of positive antibodies (anti-GAD, anti-TPO, anti-Tg), thyroid diseases, thyroid treatment and
Levothyroxine supplementation
Group 1 Group 2 Group 3 Total Statistical significance
Anti – GAD 0 (0.0%) 0 (0.0%) 1 (3.0%) 1 (2.3%) ns
Anti – TPO 2 (10.0%) 3 (50.0%) 24 (24.5%) 29 (23.4%) ns
Anti – Tg 2 (10.0%) 2 (33.3%) 18 (18.6%) 22 (17.9%) ns
Hypothyroidism 13 (28.3%) 4 (44.4%) 54 (40.6%) 71 (37.8%) ns
Hyperthyroidism 8 (17.4%) 3 (33.3%) 55 (41.4%) 66 (35.1%) p < 0.05
AITD 13 (28.3%) 4 (44.4%) 28 (21.1%) 45 (23.9%) ns
Goitre 28 (60.9%) 1 (11.1%) 51 (38.3%) 80 (42.6%) p < 0.01
With AITD 5 (10.9%) 0 (0.0%) 6 (4.5%) 11 (5.9%) ns
Without AITD 23 (50.0%) 1 (11.1%) 45 (33.8%) 69 (36.7%) p < 0.05
AFT 2 (4.4%) 0 (0.0%) 8 (6.1%) 10 (5.3%) ns
Carcinoma 0 (0.0%) 1 (11.1%) 3 (2.3%) 4 (2.1%) ns
Thyroid treatment 45 (97.8%) 6 (66.7%) 90 (67.7%) 141 (75.0%) p < 0.001
Levothyroxine 41 (89.1%) 5 (55.6%) 69 (51.9%) 115 (61.2%) p < 0.001
Group definition: Thyroid disease diagnosed prior to (group 1), within the same year (group 2) or after (group 3) diabetes onset.
Thyroid treatment: Including partial and complete thyroidectomy, radioiodine and oral medication.
anti-GAD: autoantibodies against glutamate decarboxylase; anti-TPO: autoantibodies against thyroid peroxidase; anti-Tg: autoantibodies against thyroglobulin;
AITD: autoimmune thyroid disease; AFT: autonomously functioning thyroid.
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the groups remained statistically significant (p = 0.002).
Furthermore, patients in group 1 suffered most frequently
from goitre, significantly fewer were found in group 2 (p <
0.01) and group 3 (p < 0.01).
The small size of group 2 (n = 9) makes it difficult to
compare it with the other groups, but we decided to
keep this group in the retrospective analysis, since it
comprises the clinical relevant co-diagnosed comorbidity
in contrast to either chronic conditions known for lon-
ger times or later diagnosed disease that needs to be
born in mind as potential to be screened for. We com-
pared all our results before and after exclusion of group
2 from the analysis. No difference was found except in
the comparison regarding frequency of hyperthyroidism,
which showed a statistical significance of p < 0.01 instead
of p < 0.05.
Discussion
Diabetes patients run a higher risk of developing thyroid
disorders [3,4,16,17]. In both the general population [1]
and diabetes patients [3] thyroid diseases were reported
to be more common in women than in men. Our results
confirm this in German inpatient diabetes patients, as
women (62.2%) were more frequently affected than men
(37.8%).
By metabolic comparison type 2 diabetes patients
showed significantly lower HbA1c when they had thy-
roid disease (7.2% vs. 7.5%; p < 0.01). This difference
may mark the cohort with thyroid comorbidity to be dis-
tinct but missing information on compliance and dosage
of thyroid as well as antidiabetic medication necessitatefurther studies to clarify this. However, other studies did
not report any difference in HbA1c levels between type 2
diabetes patients with and without thyroid dysfunction
[18-20]. In patients with type 1 diabetes Mohn et al. re-
ported an association between symptomatic hypoglycemia
and subclinical hypothyroidism without significant changes
in HbA1c levels [16]. Thus, our results might not directly
be attributable to thyroid comorbidity.
Whether thyroid disorders develop prior to or after dia-
betes may affect prognosis and metabolic control. In this
study the majority of the diabetes patients developed their
thyroid disease after diabetes onset. This can be explained
by the increasing prevalence of thyroid disorders with ad-
vancing age as described in various studies [2,21] and con-
firmed by our results. Furthermore, following diabetes
onset the patients are screened for thyroid disorders.
However, our results underscore that diabetes patients are
more susceptible to thyroid disorders [3,4,16,17].
In order to assess the different course of disease to in-
sulin treatment of type 2 diabetes we analysed the
insulin-free period dependent on the time of thyroid dis-
ease manifestation. A significantly earlier requirement of
insulin therapy was observed in patients with thyroid
disease onset prior to (group 1; 2.5 yrs; Q1 = 0.0, Q3 =
8.25) or within the same year (group 2; 0.0 yrs; Q1 = 0.0,
Q3 = 0.75) of diabetes mellitus onset. This suggests that
pre-existing thyroid disease may dysregulate metabolic
control in newly diagnosed diabetes necessitating earlier
insulin therapy. Maratou et al. [9] as well as Mohn et al.
[11] already showed subclinical hypo- and hyperthyroid-
ism may impact on glucose metabolism, an earlier re-
quirement for insulin, however, has not been described
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endocrine disorders (group 2) required more often im-
mediate insulin therapy despite their diagnosis of type 2
diabetes. A simultaneous disturbance of pancreatic and
thyroidal metabolism deteriorates metabolic control and
residual beta-cell function. Another study on diabetes pa-
tients without thyroid disorders showed treatment fail-
ure to sulfonylureas after a mean of 8.7 years in contrast
to our group 1 and 2 patients who required insulin con-
siderably earlier [22]. The insulin-free period in that
study was not different to ours in group 3 (8.0 yrs; Q1 =
3.0, Q3 = 12.0). This confirms the difficulty of treating dia-
betes patients with coexistent thyroid disease. However,
there are varying study criteria in the reports. We did not
differentiate the antidiabetic treatments before insulin and
had no information on whether insulin treatment was ini-
tiated after oral mono- or combination therapy.
In addition, there are further limitations: The high
BMI ranging from 28.1 to 30.6 kg/m2 and the lack of
anti-GAD autoantibody positivity in all groups make a
diagnosis of type 2 diabetes mellitus very likely. How-
ever, latent autoimmune diabetes in adults (LADA) can-
not be ruled out due to the lack of information on anti-
GAD antibodies. Janka et al. reported that up to 10% of
German type 2 diabetes patients may suffer from LADA
[23] and patients with an autoimmune thyroid disease
have an even higher risk of LADA. The earlier insulin
requirement in our groups 1 and 2 may partly be an in-
dication of underlying LADA. Also, in about 40% of our
patients thyroid disease manifestation in relation to dia-
betes onset remained unclear. Although we cannot ex-
clude that this introduces a selection bias, we regard it
as a reflection of the fact that thyroid disorders are fre-
quently neglected and time of onset more often forgot-
ten than other disorders. Future studies will therefore
need to document a full autoimmune status regarding
diabetes mellitus and thyroid diseases.
BMI indicates insulin resistance and correlates inversely
with beta-cell function [24,25]. We analysed the correlation
between insulin-free period and BMI of our patients, but
could not observe any. This result is in agreement with a
French study in which insulin-dependent type 2 diabetes
patients exhibited similar BMI to non-insulin-dependent
patients [26]. However, age at diabetes onset and insulin-
free period was inversely related: The later type 2 diabetes
became manifest, the earlier patients needed insulin ther-
apy, where about 13% variability of the insulin-free period
is attributed to the age at diabetes onset. Our finding is
compatible with another study in which the period of oral
drug administration in patients who developed diabetes be-
fore the age of 50 was effectively longer than in patients
with later onset of disease [22]. Older patients might have
had undetected diabetes for a longer time span. Also eld-
erly patients are more prone to develop a decline ofbeta-cell function. Thus, advanced age at diabetes onset in
our groups 1 and 2 can partially be attributable for their
earlier insulin requirement.
Previous studies suggest a relationship between posi-
tivity of islet cell antibodies and failure of oral antidia-
betic drugs in type 2 diabetes where insulin deficiency
explains therapy failure. Also thyroid antibodies were
more frequent in non-responders [27,28]. In agreement
with results of previous studies, we found positive anti-
TPO and anti-Tg titres were most frequently in the
group with immediate need of insulin treatment, al-
though this was not significant due to the limited num-
ber of patients.
We confirm the increasing prevalence of thyroid disor-
ders with advancing age, but this is most pertinent with
hyperthyroidism. This explains the high percentage of
patients with hyperthyroidism in our group 3. Neverthe-
less excluding patients with hyperthyroidism still showed
a significant difference in the insulin-free period between
the groups.
Conclusion
Our retrospective study suggests an interaction of thyroid
diseases with metabolic control in type 2 diabetes resulting
in an earlier need of insulin treatment. Patients with com-
pensated as well as newly diagnosed thyroid disorders re-
quired significantly earlier insulin therapy compared to
patients without thyroid diseases at the time of diabetes
onset. These data reinforce that diabetes patients with thy-
roid comorbidity need more endocrine attention. Due to
the retrospective design, the limited number of patients
and the high percentage of missing data in some patient
groups our results need to be interpreted with caution.
Further studies are needed to confirm our findings and
elucidate mechanisms of interaction of thyroid disease in
type 2 diabetes patients.
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